Takeda Pharma (TKPYY) 22.3400 $TKPYY
Novo Nordisk's Saxenda Gets Positive Opinion for Obesity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:10PM CDT
Novo Nordisk's (NVO) Saxenda received a favorable vote from the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for chronic weight management.
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles
M2 - Fri Sep 12, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl7j38/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Novartis AG - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Semafore Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - AB Science Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - motesanib diphosphate - olaratumab - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib besylate - luminespib - (dabrafenib trametinib) - pazopanib hydrochloride - binimetinib - TH-302 - SF-1126 - CS-2164 - Vaccine Targeting NY-ESO-1 for Oncology - buparlisib hydrochloride - X-82 - quizartinib - DCC-2618 - Small Molecules Targeting c-Kit for Gastrointestinal Stromal Tumor For more information visit http://www.researchandmarkets.com/research/hl...intestinal
Inflammatory Pain Therapeutics Pipeline Review 2014 - 36 Companies and 67 Drug Profiles
M2 - Thu Sep 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v44nlf/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Takeda Pharmaceutical Company Limited - Glenmark Pharmaceuticals Ltd. - Pfizer Inc. - Evotec AG - Anavex Life Sciences Corp. - Array BioPharma Inc. - Pluristem Therapeutics Inc. - BCN Peptides, S.A. - Upsher-Smith Laboratories, Inc. - Grunenthal GmbH - Integral Molecular, Inc. - AngioChem Inc. - Asahi Kasei Pharma Corp. - Hydra Biosciences, Inc. - NeurAxon, Inc. - Cara Therapeutics, Inc. - CLL Pharma - Dompe Farmaceutici S.p.A. - Lohocla Research Corporation - MAKScientific, LLC - RaQualia Pharma Inc. - Sunovion Pharmaceuticals Inc. - Adynxx, Inc. - Kareus Therapeutics, SA - AnaBios Corporation - Creabilis SA - Istituto Italiano di Tecnologia - Infirst Healthcare Limited - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v4...atory_pain
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
Takeda Responds to Judgment in Diabetes Drug Case
PR Newswire - Wed Sep 03, 12:37PM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that judgment was entered on the jury verdict that was returned on April 7, 2014, in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. (U.S. Dist. Ct., W. Dist. of Louisiana, Case No. 12-0064). The court has yet to rule on Takeda and Eli Lilly & Co.'s post-trial motion for a new trial, or alternatively, a significantly reduced punitive damage award.
Global Peptic Ulcer Drugs Market 2014-2018: Key Vendors are AstraZeneca, Eisai, Daewoong and Takeda
M2 - Fri Aug 29, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hx23pt/global_peptic) has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" report to their offering. A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer. The analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Pipeline Portfolio 09. Market Segmentation by Class of Drugs 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis Companies Mentioned: - AstraZeneca plc - Eisai Co. Ltd. - Daewoong Pharmaceutical Co. Ltd. - Takeda Pharmaceutical Co. Ltd. - Daiichi Sankyo - Dr. Reddy's Laboratories - Eumedica - Ferring Pharmaceuticals - Horizon Pharma - Johnson and Johnson - Merck Sharp and Dohme - Otsuka Holdings - Pfizer - PharmaKing - Pozen - Rottapharm Madaus - Taiho Pharmaceutical - Zeria Pharmaceutical and Zuventus Healthcare For more information visit http://www.researchandmarkets.com/research/hx...bal_peptic
Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS
PR Newswire Europe - Thu Aug 28, 11:52AM CDT
-- No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study
Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone
GlobeNewswire - Thu Aug 21, 3:30PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that its subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply agreement (EMSA) with its manufacturing and development partner, R-Tech Ueno, Ltd. (R-Tech), for clinical and commercial supplies of AMITIZA (lubiprostone) in most global markets.
The Lanier Law Firm Attorneys in Houston, New York Listed Among Nation's Best
PR Newswire - Wed Aug 20, 9:20AM CDT
The Lanier Law Firm founder Mark Lanier and firm attorney Richard "Rick" Meadow once again are being recognized as two of the country's top lawyers in the annual listing of The Best Lawyers in America. The 2015 edition marks the 10th year Mr. Lanier has been listed among the nation's best based on his work in commercial litigation and plaintiffs' mass tort class actions.
AstraZeneca's Gout Drug in Focus with Phase III Data Readout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 3:45PM CDT
AstraZeneca (AZN) announced top-line results from three phase III studies.
Alnylam's Q2 Loss Wider-than-Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:40AM CDT
Alnylam Pharmaceuticals Inc.'s (ALNY) second quarter 2014 loss of 63 cents per share was wider than the Zacks Consensus Estimate of a loss of 54 cents.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
Seattle Genetics Up on Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 3:20PM CDT
Seattle Genetics reported second-quarter loss per share of 14 cents, narrower than the Zacks Consensus Estimate of a loss of 22 cents.
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:50PM CDT
AMAG's (AMAG) second quarter loss narrowed on the back of increased Feraheme sales.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Lawsuit Settlement News Reports Bad Pharmaceutical Drug Cases Are Ongoing While Funding For Cash Advances and Free Attorney Legal Consultations Are Available
PR Newswire - Thu Jul 17, 4:00AM CDT
MT Services LLC, a Lawsuit Settlement News Reporting Company, which operates lawsuitsettlementnews.com announced today a primary focus on assisting plaintiffs of bad pharmaceutical drugs such as AndgroGel: Testosterone Creams, Accutane, Acetaminophen, Actos, Avandia, Byetta-Januvia-Victoza, Birth Control Products: Yaz, Yasmin, Ocella, Mirena, NuvaRing, Chantix, Crestor, Depakote, Fosamax, Granuflo, Lexapro, Lipitor, Paxil, Prempro, Pradaxa, Reglan, Risperdal, Steroid/Epidural Shots Causing Meningitis, Topamax, Viagra, Zoloft or others not listed on finding legal assistance with obtaining a pharmaceutical lawyer or law firm.
Novo Nordisk's Saxenda Gets Positive Opinion for Obesity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:10PM CDT
Novo Nordisk's (NVO) Saxenda received a favorable vote from the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for chronic weight management.
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles
M2 - Fri Sep 12, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl7j38/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Novartis AG - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Semafore Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - AB Science Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - motesanib diphosphate - olaratumab - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib besylate - luminespib - (dabrafenib trametinib) - pazopanib hydrochloride - binimetinib - TH-302 - SF-1126 - CS-2164 - Vaccine Targeting NY-ESO-1 for Oncology - buparlisib hydrochloride - X-82 - quizartinib - DCC-2618 - Small Molecules Targeting c-Kit for Gastrointestinal Stromal Tumor For more information visit http://www.researchandmarkets.com/research/hl...intestinal
Inflammatory Pain Therapeutics Pipeline Review 2014 - 36 Companies and 67 Drug Profiles
M2 - Thu Sep 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v44nlf/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Takeda Pharmaceutical Company Limited - Glenmark Pharmaceuticals Ltd. - Pfizer Inc. - Evotec AG - Anavex Life Sciences Corp. - Array BioPharma Inc. - Pluristem Therapeutics Inc. - BCN Peptides, S.A. - Upsher-Smith Laboratories, Inc. - Grunenthal GmbH - Integral Molecular, Inc. - AngioChem Inc. - Asahi Kasei Pharma Corp. - Hydra Biosciences, Inc. - NeurAxon, Inc. - Cara Therapeutics, Inc. - CLL Pharma - Dompe Farmaceutici S.p.A. - Lohocla Research Corporation - MAKScientific, LLC - RaQualia Pharma Inc. - Sunovion Pharmaceuticals Inc. - Adynxx, Inc. - Kareus Therapeutics, SA - AnaBios Corporation - Creabilis SA - Istituto Italiano di Tecnologia - Infirst Healthcare Limited - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v4...atory_pain
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
Takeda Responds to Judgment in Diabetes Drug Case
PR Newswire - Wed Sep 03, 12:37PM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that judgment was entered on the jury verdict that was returned on April 7, 2014, in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. (U.S. Dist. Ct., W. Dist. of Louisiana, Case No. 12-0064). The court has yet to rule on Takeda and Eli Lilly & Co.'s post-trial motion for a new trial, or alternatively, a significantly reduced punitive damage award. Global Peptic Ulcer Drugs Market 2014-2018: Key Vendors are AstraZeneca, Eisai, Daewoong and Takeda
M2 - Fri Aug 29, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hx23pt/global_peptic) has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" report to their offering. A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer. The analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Pipeline Portfolio 09. Market Segmentation by Class of Drugs 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis Companies Mentioned: - AstraZeneca plc - Eisai Co. Ltd. - Daewoong Pharmaceutical Co. Ltd. - Takeda Pharmaceutical Co. Ltd. - Daiichi Sankyo - Dr. Reddy's Laboratories - Eumedica - Ferring Pharmaceuticals - Horizon Pharma - Johnson and Johnson - Merck Sharp and Dohme - Otsuka Holdings - Pfizer - PharmaKing - Pozen - Rottapharm Madaus - Taiho Pharmaceutical - Zeria Pharmaceutical and Zuventus Healthcare For more information visit http://www.researchandmarkets.com/research/hx...bal_peptic
Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS
PR Newswire Europe - Thu Aug 28, 11:52AM CDT
-- No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study
Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone
GlobeNewswire - Thu Aug 21, 3:30PM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that its subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply agreement (EMSA) with its manufacturing and development partner, R-Tech Ueno, Ltd. (R-Tech), for clinical and commercial supplies of AMITIZA (lubiprostone) in most global markets.
The Lanier Law Firm Attorneys in Houston, New York Listed Among Nation's Best
PR Newswire - Wed Aug 20, 9:20AM CDT
The Lanier Law Firm founder Mark Lanier and firm attorney Richard "Rick" Meadow once again are being recognized as two of the country's top lawyers in the annual listing of The Best Lawyers in America. The 2015 edition marks the 10th year Mr. Lanier has been listed among the nation's best based on his work in commercial litigation and plaintiffs' mass tort class actions.
AstraZeneca's Gout Drug in Focus with Phase III Data Readout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 3:45PM CDT
AstraZeneca (AZN) announced top-line results from three phase III studies.
Alnylam's Q2 Loss Wider-than-Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:40AM CDT
Alnylam Pharmaceuticals Inc.'s (ALNY) second quarter 2014 loss of 63 cents per share was wider than the Zacks Consensus Estimate of a loss of 54 cents.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
Seattle Genetics Up on Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 3:20PM CDT
Seattle Genetics reported second-quarter loss per share of 14 cents, narrower than the Zacks Consensus Estimate of a loss of 22 cents.
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:50PM CDT
AMAG's (AMAG) second quarter loss narrowed on the back of increased Feraheme sales.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Lawsuit Settlement News Reports Bad Pharmaceutical Drug Cases Are Ongoing While Funding For Cash Advances and Free Attorney Legal Consultations Are Available
PR Newswire - Thu Jul 17, 4:00AM CDT
MT Services LLC, a Lawsuit Settlement News Reporting Company, which operates lawsuitsettlementnews.com announced today a primary focus on assisting plaintiffs of bad pharmaceutical drugs such as AndgroGel: Testosterone Creams, Accutane, Acetaminophen, Actos, Avandia, Byetta-Januvia-Victoza, Birth Control Products: Yaz, Yasmin, Ocella, Mirena, NuvaRing, Chantix, Crestor, Depakote, Fosamax, Granuflo, Lexapro, Lipitor, Paxil, Prempro, Pradaxa, Reglan, Risperdal, Steroid/Epidural Shots Causing Meningitis, Topamax, Viagra, Zoloft or others not listed on finding legal assistance with obtaining a pharmaceutical lawyer or law firm.
